742 / 1631
ibrutinib
®
delivered high response
rates in relapsed/refractory MCL.
1
•
Responses were often seen early
(median 1.9 months to initial
response) and generally
continued to improve over time
1
Phase II study
Response rates
MCL: mantle cell lymphoma.
1. Wang M et al. N Engl J Med 2013; 369: 507-516.
High response rates in relapsed/refractory MCL
1
Partial response: Regression of measurable disease and no new sites.
2
Complete response: Disappearance of all evidence of disease.
2
(Revised International Working Group Criteria for non-Hodgkin’s lymphoma)
Graph adapted from WangM, etal. 2013.